Search Results - "Addamo, G F"

Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients by Toma, S, Repetto, L, Giacchero, A, Coialbu, T, Costantini, M, Addamo, G F, Guido, T, Rosso, R

“…147 stage II pre- and perimenopausal breast cancer patients were treated with cyclophosphamide-methotrexate-5-fluorouracil (CMF)- based adjuvant regimens. 103…”
Get more information

High dose intensity chemotherapy without bone marrow support: role of granulocyte-macrophage colony-stimulating factor by Venturini, M, Del Mastro, L, Ardizzoni, A, Sertoli, M R, Mariani, G L, Pennucci, M C, Garrone, O, Silvestro, S, Addamo, G F, Queirolo, P

Get more information

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force by Ardizzoni, A, Addamo, G F, Baldini, E, Borghini, U, Portalone, L, De Marinis, F, Lionetto, R, Conte, P F, Bruzzi, P, Pennucci, M C

“…The FONICAP group is screening, with randomised phase II studies, the activity of new chemotherapy programmes for advanced non-small-cell lung cancer (NSCLC)…”
Get full text

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study by Ardizzoni, A, Addamo, GF, Baldini, E, Borghini, U, Portalone, L, De Marinis, F, Lionetto, R, Conte, PF, Bruzzi, P, Pennucci, MC

Get full text

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-lung cancer : a FONICAP randomised phase II study by ARDIZZONI, A, ADDAMO, G. F, VENTURINI, M, RINALDI, M, ROSSO, R, SALVATI, F, BALDINI, E, BORGHINI, U, PORTALONE, L, DE MARINIS, F, LIONETTO, R, CONTE, P. F, BRUZZI, P, PENNUCCI, M. C

Get full text